November 20, 2021
Video
The treatment was effective across all weight groups.
November 18, 2021
Article
More than 90% of patients in hypertension and lipid management accomplished their predetermined goals after completing the remote program.
November 17, 2021
After 1 year, 37% of patients had died and 65% of patients were readmitted to the hospital.
Bentracimab achieved the predetermined primary endpoint of immediate and sustained reversal of the antiplatelet effects of ticagrelor in the REVERSE-IT trial.
Young smokers in 2017 were more likely to have other comorbid conditions including hypertension, diabetes, and obesity.
November 16, 2021
A new study from the American Heart Association Scientific Sessions 2021 found that atherosclerotic cardiovascular disease risk increases with sdLDL-C levels, regardless of sex or race.
There was a 135% reduction in platelet inhibition observed within 5-10 minutes following bentracimab infusion.
Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.
November 21, 2019
In a presentation at AHA, T. Jared Bunch, MD, discusses how early detection of AF could yield positive results down the line for patients.
Why US patients are now in absolute need of proven measures to lessen their risk of cardiovascular burden.
Patients With Vitiligo Report Varied Severe Symptoms Based on Skin Tone
Ruxolitinib Beneficial Across Demographics of Patients with Vitiligo
Promising Data from InPedILD Phase 3 Trial Revealed at ERS Congress 2022
